Braveheart Bio, Inc.

BRVE Nasdaq SEC CIK 2131524
Follow Braveheart Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$26.5M +55.2% vs same quarter last year
EPS, diluted −$0.51 +94.9% vs same quarter last year
Operating cash flow −$24.4M −3193.6% vs same quarter last year
Operating income −$30.1M +49.1% vs same quarter last year
Net income by quarter
−$99K
−$381K
−$59.1M
−$14.3M
−$15M
−$26.5M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing